NEW YORK (GenomeWeb) – Ariosa Diagnostics has priced its planned initial public offering of 3.5 million shares.

In an amended Form S-1 filed with the US Securities and Exchange Commission on Thursday, the company priced its common shares at a range of $16 to $18 per share. At the $17 midpoint price, the offering would bring in net proceeds of $52.3 million, the San Jose, Calif.-based non-invasive prenatal testing firm said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Heads of various research funding agencies discuss how to encourage scientific breakthroughs, ScienceInsider reports.

The Kansas City Star examines issues surrounding newborn genome sequencing.

Researchers say their Research Resource Identifier citation format is catching on, Nature News reports.

In Science this week: the Human Silencing Hub protein complex, and more.